Advertisement
Advertisement
U.S. markets open in 7 hours 7 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Rani Therapeutics Holdings, Inc. (RANI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
21.76-3.92 (-15.26%)
At close: 04:00PM EST
21.80 +0.04 (+0.18%)
After hours: 04:13PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close25.68
Open26.38
Bid0.00 x 900
Ask0.00 x 1200
Day's Range21.36 - 26.55
52 Week Range9.24 - 36.27
Volume83,857
Avg. Volume92,198
Market Cap428.931M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.01
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RANI

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Rani Therapeutics Holdings, Inc
    Daily – Vickers Top Buyers & Sellers for 11/08/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    28 days agoArgus Research
View more
  • GlobeNewswire

    Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update

    SAN JOSE, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the quarter ended September 30, 2021, and provided a corporate update. “I am pleased with the progress Rani has made since our IPO. As we build a solid foundation for being a successful public company, we are laser focused on creating value and a

  • GlobeNewswire

    Rani Therapeutics Appoints Lyn Baranowski to Board of Directors

    SAN JOSE, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the appointment of Lyn Baranowski to its Board of Directors. Ms. Baranowski is a distinguished biotechnology executive with nearly two decades of experience. “Lyn is a well-respected biotechnology executive whose dee

  • GlobeNewswire

    Rani Therapeutics to Participate in a Fireside Chat at the Stifel 2021 Virtual Healthcare Conference

    SAN JOSE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (NASDAQ: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021, at 7:00 a.m. PT / 10:00 a.m. ET. Interested parties can access the live audio webcast for this conference from the Investor Relations secti

Advertisement
Advertisement